OXFORD, England, December 17 /PRNewswire/ --
- New Deal Provides a Further Opportunity for OGeS to Grow its Therapeutic Antibody Pipeline
Oxford Genome Sciences (UK) Ltd "OGeS" announces today that it has entered into a strategic collaboration with Amgen to discover, develop and commercialise novel therapeutic antibodies for the treatment of cancer. This new collaboration will enable OGeS to further strengthen its pipeline of fully human therapeutic antibodies (mAbs) in cancer based on the target discovery capabilities of its unique OGAP(R) database.
Under the collaboration, OGeS and Amgen will jointly discover novel antibodies for the treatment of cancer. The companies will generate fully human antibodies using Amgen's XenoMouse(R) technology, which was acquired through its acquisition of Abgenix. These antibodies will be raised against the novel druggable targets that OGeS has identified through its unique Oxford Genome Anatomy Project (OGAP(R)) database. OGAP has been developed into the world's largest cancer protein database, to discover novel clinically relevant drug targets and diagnostics.
Today's agreement covers up to six oncology programmes. Amgen will have the right to select up to three programmes, while OGeS will retain rights to the remainder. Once Amgen has produced the initial antibody leads, OGeS will carry out the initial pre-clinical assessment of each antibody programme.
Dr Christian Rohlff, CEO of OGeS, commented: "I am very happy to be
collaborating with Amgen in our effort to discover and develop novel fully
human antibodies for the treatment of cancer. I am confident that by using
our complementary expertise we will be able to develop a promising and
valuable pipeline of antibodies. This significant new deal, together with
our existing Medarex collaboration, further underpins OGeS' transition from
a target discovery to a product development company and is an important
|SOURCE Oxford Genome Sciences|
Copyright©2007 PR Newswire.
All rights reserved